Nasal drug delivery has traditionally been used for local, inflammatory conditions within the sinus cavity, such as rhinitis and nasal congestion. In recent years however, it has evolved into a versatile route for systemic drug uptake via the nasal epithelium, intranasal vaccination and even emerging nose-to-brain delivery. This evolution has made nasal administration a promising route for both new chemical entities (NCEs) and reformulated therapies with patent-expired formulations.¹

As applications grow, so does complexity. Every nasal product is unique, defined by where it needs to act, how quickly it needs to work and how it needs to be delivered. Developers must navigate formulation and device challenges, from mucosal clearance to bioavailability, whilst meeting stringent manufacturing and regulatory demands. These factors are driving more innovators to partner with specialist contract development and manufacturing organisations (CDMOs) with the expertise, technology and facilities to help scale their bespoke nasal drug-device combination products to the clinic and beyond.

Next-Generation Nasal Applications

As a route of drug administration, the nasal cavity offers several advantages over oral, intravenous and even pulmonary delivery. Its highly vascularised epithelium allows for rapid drug uptake. Additionally, bypassing first-pass metabolism can enhance the bioavailability of certain therapies. Intranasal delivery can also generate strong immune responses, making intranasal vaccination particularly attractive. Beyond this, nasal administration can offer improved patient experience and compliance through non-invasive, needle-free delivery.